2022
33-OR: ADA Presidents' Select Abstract: Glycemic Outcomes over 12 Months in Very Young Children with the Omnipod 5 Automated Insulin Delivery (AID) System
DESALVO D, BODE B, FORLENZA G, LAFFEL L, BUCKINGHAM B, CRIEGO A, SCHOELWER M, MACLEISH S, SHERR J, HANSEN D, LY T. 33-OR: ADA Presidents' Select Abstract: Glycemic Outcomes over 12 Months in Very Young Children with the Omnipod 5 Automated Insulin Delivery (AID) System. Diabetes 2022, 71 DOI: 10.2337/db22-33-or.Peer-Reviewed Original ResearchDiabetic ketoacidosisSevere hypoglycemiaMannKind CorporationGlycemic outcomesExtension studyEpisodes of diabetic ketoacidosisOccurrence of severe hypoglycemiaNational Institute of DiabetesDigestive and Kidney DiseasesCenter for Health ResearchChildren aged 2Type 1 diabetesStandard therapySafety endpointsPivotal studiesPotential long-term benefitsKidney diseaseStudy groupGlucose targetsLong-term benefitsSpeakers bureauImprove glycemic outcomesAged 2MedtronicGlycemic benefits765-P: Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years
SCHOELWER M, BODE B, CARLSON A, CRIEGO A, FORLENZA G, WEINSTOCK R, HANSEN D, BUCKINGHAM B, MEHTA S, LAFFEL L, SHERR J, LEVY C, HIRSCH I, MACLEISH S, DESALVO D, SHAH V, BHARGAVA A, JONES T, ALEPPO G, GURLIN R, LY T. 765-P: Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years. Diabetes 2022, 71 DOI: 10.2337/db22-765-p.Peer-Reviewed Original ResearchDaily insulin doseMannKind CorporationInsulin doseGlycemic outcomesEvaluate glycemic outcomesHigher TIRNational Institute of DiabetesDigestive and Kidney DiseasesCenter for Health ResearchType 1 diabetesEli Lilly and CompanySpeakers bureauInsulin requirementsAid useKidney diseaseInsulin needsMannKindCohort of peopleMedtronicTherapy phaseAged 2Janssen PharmaceuticalsOlder ageDiabetesT1D100-LB: Glycemic Control Using Recommended Settings in Youth and Adults with Type 1 Diabetes (T1D) —Minimed 780G System with the Calibration-Free Guardian 4 Sensor Results
VIGERSKY R, BODE B, BRAZG R, BUCKINGHAM B, CARLSON A, KAISERMAN K, KIPNES M, LILJENQUIST D, PHILIS-TSIMIKAS A, PIHOKER C, POP-BUSUI R, REED J, SHERR J, SHULMAN D, SLOVER R, THRASHER J, CHEN X, LIU M, CORDERO T, VELLA M, RHINEHART A, SHIN J. 100-LB: Glycemic Control Using Recommended Settings in Youth and Adults with Type 1 Diabetes (T1D) —Minimed 780G System with the Calibration-Free Guardian 4 Sensor Results. Diabetes 2022, 71 DOI: 10.2337/db22-100-lb.Peer-Reviewed Original ResearchMannKind CorporationSpeakers bureauKidney diseaseNovo NordiskEli LillyAdvisory PanelNational InstituteHealth researchMonths of useEffectiveness endpointReata PharmaceuticalsGlycemic controlPivotal trialsSevere hypoglycemiaEffectiveness outcomesGlycemic metricsDiabetesBayer AGHealth groupsRoche DiagnosticsUnitedHealth GroupLexicon PharmaceuticalsMiniMedTarget rangeSanofi
2021
70-OR: Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes (T1D)
SHERR J, BODE B, FORLENZA G, LAFFEL L, BROWN S, BUCKINGHAM B, CRIEGO A, DESALVO D, MACLEISH S, HANSEN D, LY T. 70-OR: Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes (T1D). Diabetes 2021, 70 DOI: 10.2337/db21-70-or.Peer-Reviewed Original ResearchDiabetes careDiabetic ketoacidosisStandard therapySevere hypoglycemiaSpeakers bureauEli LillyYoung childrenPrimary safety outcomePrimary effectiveness outcomeSerious adverse eventsAdvisory PanelLexicon PharmaceuticalsDaily dose requirementsType 1 diabetesNovo NordiskBoehringer Ingelheim PharmaceuticalsMannKind CorporationPermissive hyperglycemiaBaseline characteristicsHybrid closed-loop systemT1D durationAdverse eventsGlucose targetsEfficacy analysisInsulin delivery systems
2020
1296-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Children Aged 2-12 Years without Increasing Risk of Hypoglycemia
SHERR J, BUCKINGHAM B, FORLENZA G, GALDERISI A, EKHLASPOUR L, WADWA R, ZGORSKI M, KINGMAN R, BERGET C, LEE J, OCONNOR J, DUMAIS B, VIENNEAU T, HUYETT L, LY T. 1296-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Children Aged 2-12 Years without Increasing Risk of Hypoglycemia. Diabetes 2020, 69 DOI: 10.2337/db20-1296-p.Peer-Reviewed Original ResearchDiabetes careGlucose targetsEli LillySerious adverse eventsHigh-fat mealRisk of hypoglycemiaAdvisory PanelType 1 diabetesChildren Aged 2MannKind CorporationHybrid closed-loop systemT1D durationAdverse eventsT1D ExchangeFat mealGlucose managementMean glucosePivotal studiesAged 2Bolus challengeDaily exerciseInvestigational deviceDlPercent timeTarget glucose978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia
FORLENZA G, BUCKINGHAM B, SHERR J, WADWA R, GALDERISI A, EKHLASPOUR L, BERGET C, HSU L, ZGORSKI M, LEE J, OCONNOR J, DUMAIS B, VIENNEAU T, HUYETT L, LY T. 978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia. Diabetes 2020, 69 DOI: 10.2337/db20-978-p.Peer-Reviewed Original ResearchDiabetes careMeal bolusEli LillyPercent timeRisk of hypoglycemiaAdvisory PanelType 1 diabetesHigh-fat dinnerMannKind CorporationHybrid closed-loop systemT1D durationGlucose targetsT1D ExchangeGlucose managementPivotal studiesDaily exerciseInvestigational deviceDlTarget glucoseCareLexicon PharmaceuticalsMedtronicBolusLower targetsAdults
2019
1424-P: Changes in Device Uptake and Glycemic Control among Pregnant Women with Type 1 Diabetes: Data from the T1D Exchange
LEVY C, FOSTER N, DUBOSE S, AGARWAL S, LYONS S, PETERS A, UWAIFO G, DIMEGLIO L, SHERR J, POLSKY S. 1424-P: Changes in Device Uptake and Glycemic Control among Pregnant Women with Type 1 Diabetes: Data from the T1D Exchange. Diabetes 2019, 68 DOI: 10.2337/db19-1424-p.Peer-Reviewed Original ResearchPregnant womenMannKind CorporationSanofi USKidney diseaseDiabetes FoundationPump useT1D Exchange Clinic RegistryEli LillyLexicon PharmaceuticalsBarbara Davis CenterInsulin pump useCohort of womenType 1 diabetesReal-world populationNational InstituteAdvisory PanelHelmsley Charitable TrustHealth researchPregnancy outcomesGlycemic controlSevere hypoglycemiaClinic registrySelf-reported useT1D ExchangeNovo Nordisk A/S2418-PUB: Incident Diabetes Complications among Women with T1D Based on Parity
POLSKY S, FOSTER N, DUBOSE S, AGARWAL S, LYONS S, PETERS A, UWAIFO G, DIMEGLIO L, SHERR J, LEVY C. 2418-PUB: Incident Diabetes Complications among Women with T1D Based on Parity. Diabetes 2019, 68 DOI: 10.2337/db19-2418-pub.Peer-Reviewed Original ResearchStudy enrollmentMannKind CorporationSanofi USKidney diseaseDiabetes FoundationT1D Exchange Clinic RegistryCardiovascular disease risk factorsEli LillyRate of neuropathyDisease risk factorsDiabetes-related complicationsLexicon PharmaceuticalsBarbara Davis CenterBody mass indexType 1 diabetesNational InstituteAdvisory PanelHelmsley Charitable TrustHealth researchYear of enrollmentRace/ethnicityPreg groupPregnant cohortClinic registryMass index
2018
Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes (T1D)
MEHTA S, WU M, FOSTER N, POP-BUSUI R, KATZ M, CRANDALL J, BACHA F, NADEAU K, LIBMAN I, HIERS P, MIZOKAMI-STOUT K, DIMEGLIO L, SHERR J, PRATLEY R, AGARWAL S, SNELL-BERGEON J, CENGIZ E, POLSKY S, SHAH V. Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes (T1D). Diabetes 2018, 67 DOI: 10.2337/db18-15-lb.Peer-Reviewed Original ResearchCVD risk factorsIncident cardiovascular diseaseRisk factorsCardiovascular diseaseDiabetic nephropathyT1D Exchange Clinic RegistryTraditional CVD risk factorsEli LillyPediatric Diabetes ConsortiumBlood pressure medicationsIschemic heart diseaseImportant risk factorType 1 diabetesNon-fatal eventsNational InstituteYears of ageBoehringer Ingelheim PharmaceuticalsAdvisory PanelEisai Inc.MannKind CorporationDiabetes durationComposite outcomeHeart failureClinic registryContemporary cohortIncreased HbA1c Variability May Shorten Time to Microalbuminuria Development in Type 1 Diabetes (T1D)
CLEMENTS M, WU M, FOSTER N, LAFFEL L, SHAH V, VENDRAME F, KINGMAN R, ALONSO G, CARLSON A, DESALVO D, BUCKINGHAM B, SHERR J, BENJAMIN R, EYTH E, DUBOSE S. Increased HbA1c Variability May Shorten Time to Microalbuminuria Development in Type 1 Diabetes (T1D). Diabetes 2018, 67 DOI: 10.2337/db18-26-lb.Peer-Reviewed Original ResearchRisk of microalbuminuriaSD HbA1cDiabetes careT1D Exchange Clinic RegistryShorter diabetes durationSpeakers bureauType 1 diabetesAge of diagnosisEli LillyBoehringer Ingelheim PharmaceuticalsAdvisory PanelMannKind CorporationMicroalbuminuria developmentSanofi USDiabetes durationMean HbA1cT1D durationRenal diseaseClinic registryRegistry enrollmentClinic visit recordsT1D populationMedian numberMicroalbuminuriaDiabetes Institute